The Druckenmiller play on RAS
Billionaire investor Stanley Druckenmiller made a major commitment to the biotech sector in the first quarter of 2026 by investing $30.7 million in Revolution Medicines. His investment firm, the Duquesne Family Office, which manages around $3 billion in assets, has a long history of backing aggressive clinical-stage biotech companies. Revolution Medicines has drawn attention for its lead drug candidate, daraxonrasib, which targets the RAS protein, a long-standing challenge in cancer research due to its complex biological behavior.
In April 2026, Revolution Medicines announced strong results from late-stage trials. Daraxonrasib increased median overall survival to 13.2 months. This is for patients with previously treated metastatic pancreatic cancer. That’s nearly double traditional chemotherapy achieves. This has significantly contributed to the stock’s 400% rise over the past year.
The math behind the move
Revolution Medicines is now valued at $40 billion. This number reflects high expectations for its future growth. If daraxonrasib achieves its lowest projected peak sales, it would be $5 billion. The company would trade at eight times revenue. This is revenue that hasn’t materialized yet. These estimates are based solely on the drug’s potential success. This is in pancreatic cancer. But Revolution is also running trials for non-small cell lung cancer. This could add billions in additional revenue. This is if the drug proves effective in that area.
Despite the ongoing FDA approval process, Revolution Medicines remains a speculative investment. Druckenmiller’s decision to build a large stake implies he believes the drug’s potential goes beyond current market expectations. Still, the company’s valuation already incorporates a significant amount of optimism, which may concern risk-averse investors.
A crowded market for risk-takers
Druckenmiller is well known for taking big risks in volatile markets. He has backed unproven therapies that could disrupt entire industries. His firm has a history of investing in high-risk opportunities. These are before they gain mainstream acceptance. But with Revolution Medicines already up 400% in a year. Some investors are starting to shift focus to other biotech names. These may offer clearer growth opportunities. This is with less uncertainty.
Analysts estimate that daraxonrasib could achieve peak sales. The range is from $5 billion to $7.6 billion. These numbers depend entirely on the drug’s success. This is in clinical trials and regulatory approvals. Even with those optimistic forecasts. The company’s current valuation remains a tough barrier. This is for many investors who prioritize more conservative bet.